title: The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.
abstract: OBJECTIVE
  To evaluate the safety and potential pharmacokinetic interaction between indinavir and clarithromycin.
  
  
  METHODS
  In a randomized, three-period, crossover fashion, 12 healthy adults received the following for 1 week: 800 mg oral indinavir sulfate every 8 hours with placebo, 500 mg oral clarithromycin every 12 hours with placebo, and indinavir sulfate with clarithromycin. Plasma indinavir, clarithromycin, and 14-hydroxyclarithromycin concentrations were determined after the last dose in each treatment period.
  
  
  RESULTS
  Administration of indinavir sulfate with clarithromycin caused a statistically significant increase in four pharmacokinetic parameters: a 58% increase in plasma indinavir concentrations at 8 hours (P = .029), a 47% increase in values for clarithromycin area under the plasma concentration versus time curve from time zero to the last measured concentration [AUC(0-12h); P = .0002], and 49% and 48% decreases in 14-hydroxyclarithromycin AUC(0-12h) and maximum plasma concentration (Cmax) values, respectively (P = .0001 and P = .0001). These effects are not considered to be clinically significant in view of the insignificant effects on the values for indinavir area under the plasma concentration versus time curve from time zero to the last measured concentration [AUC(0-8h)] and Cmax, as well as the safety profile of clarithromycin.
  
  
  CONCLUSIONS
  The combination of indinavir sulfate and clarithromycin is generally well tolerated and can be coadministered without dose adjustment.
authors.affiliation: Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, NJ, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Boruchoff
authors.forename: M G
authors.initials: MG
authors.lastname: Sturgill
authors.forename: K W
authors.initials: KW
authors.lastname: Grasing
authors.forename: J R
authors.initials: JR
authors.lastname: Seibold
authors.forename: J
authors.initials: J
authors.lastname: McCrea
authors.forename: G A
authors.initials: GA
authors.lastname: Winchell
authors.forename: S E
authors.initials: SE
authors.lastname: Kusma
authors.forename: P J
authors.initials: PJ
authors.lastname: Deutsch
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002118:Calcium / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D017291:Clarithromycin / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D014527:Uric Acid / Q000652:urine
chemical_list: D000900:Anti-Bacterial Agents; D017320:HIV Protease Inhibitors; C056228:14-hydroxyclarithromycin; D014527:Uric Acid; D019469:Indinavir; D017291:Clarithromycin; D002118:Calcium